Polyphor AG (PPHOF)
| Previous close | 2.5000 |
| Open | 2.5000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 2.5000 - 2.5000 |
| 52-week range | 2.5000 - 8.6626 |
| Volume | 1,000 |
| Avg. volume | 23 |
| Market cap | 28.021M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.3790 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by EnBiotix
Polyphor AG / Key word(s): Agreement10-Sep-2021 / 07:30 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, September 10, 2021Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by EnBiotixPolyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, today
- EQS Group
Polyphor provides final update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer
Polyphor AG / Key word(s): Study results03-Aug-2021 / 19:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, August 3, 2021Polyphor provides final update on the Phase III FORTRESS study of balixafortide in patients with advanced HER2 negative breast cancer- Primary endpoint of the study progression free survival (PFS) was not met- Pre-specified interim analysis of overall survival (OS) sh
- EQS Group
Polyphor to extend period for its strategic evaluation by up to four weeks
Polyphor AG / Key word(s): Statement30-Jul-2021 / 07:30 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, July 30, 2021Polyphor to extend period for its strategic evaluation by up to four weeksPolyphor AG (SIX: POLN) today provided an update regarding the recently announced evaluation of strategic options. This review has become necessary following the negative results of the FORTRESS stud
